Carl L Gordon - Net Worth and Insider Trading

Carl L Gordon Net Worth

The estimated net worth of Carl L Gordon is at least $721 Million dollars as of 2025-05-07. Carl L Gordon is the Director, 10% Owner of Prevail Therapeutics Inc and owns about 13,822,463 shares of Prevail Therapeutics Inc (PRVL) stock worth over $318 Million. Carl L Gordon is the Director of Turning Point Therapeutics Inc and owns about 2,027,550 shares of Turning Point Therapeutics Inc (TPTX) stock worth over $154 Million. Carl L Gordon is also the Director, 10% Owner of Theseus Pharmaceuticals Inc and owns about 17,713,600 shares of Theseus Pharmaceuticals Inc (THRX) stock worth over $72 Million. Besides these, Carl L Gordon also holds MBX Biosciences Inc (MBX) , ArriVent BioPharma Inc (AVBP) , Compass Therapeutics Inc (CMPX) , Intellia Therapeutics Inc (NTLA) , Alector Inc (ALEC) , BioCryst Pharmaceuticals Inc (BCRX) , ORIC Pharmaceuticals Inc (ORIC) , ACADIA Pharmaceuticals Inc (ACAD) , Adicet Bio Inc (ACET) , Terns Pharmaceuticals Inc (TERN) , Keros Therapeutics Inc (KROS) , Kinnate Biopharma Inc (KNTE) , Cartesian Therapeutics Inc (RNAC) , X4 Pharmaceuticals Inc (XFOR) , Pacira BioSciences Inc (PCRX) . Details can be seen in Carl L Gordon's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Carl L Gordon has not made any transactions after 2025-04-09 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data
Unlimited Filters in All-in-One Stock Screener
Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Quick Customer Support
And Much More...

Transaction Summary of Carl L Gordon

To

Carl L Gordon Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Carl L Gordon owns 22 companies in total, including Prevail Therapeutics Inc (PRVL) , Turning Point Therapeutics Inc (TPTX) , and ORIC Pharmaceuticals Inc (ORIC) among others .

Click here to see the complete history of Carl L Gordon’s form 4 insider trades.

Insider Ownership Summary of Carl L Gordon

Ticker Company Transaction Date Type of Owner
PRVL Prevail Therapeutics Inc 2020-06-17 director & 10 percent owner
TPTX Turning Point Therapeutics Inc 2019-04-22 director
ORIC ORIC Pharmaceuticals Inc 2021-03-30 director
LIMIT LIMIT 2024-08-13 director
LIMIT LIMIT 2019-09-12 director & 10 percent owner
LIMIT LIMIT 2019-02-11 director & 10 percent owner
LIMIT LIMIT 2018-06-22 director
LIMIT LIMIT 2017-11-20 director & 10 percent owner
LIMIT LIMIT 2016-05-11 director & 10 percent owner
LIMIT LIMIT 2016-06-27 director & 10 percent owner
LIMIT LIMIT 2013-09-18 director
LIMIT LIMIT 2011-02-28 director
LIMIT LIMIT 2011-02-08 director
LIMIT LIMIT 2005-12-02 director
LIMIT LIMIT 2005-04-20 director
LIMIT LIMIT 2024-01-25 director
LIMIT LIMIT 2025-04-09 director & 10 percent owner
LIMIT LIMIT 2023-07-17 director & 10 percent owner
LIMIT LIMIT 2023-05-05 director
LIMIT LIMIT 2021-10-04 director & 10 percent owner
LIMIT LIMIT 2024-07-16 director & 10 percent owner
LIMIT LIMIT 2023-02-27 10 percent owner

Carl L Gordon Latest Holdings Summary

Carl L Gordon currently owns a total of 18 stocks. Among these stocks, Carl L Gordon owns 13,822,463 shares of Prevail Therapeutics Inc (PRVL) as of June 24, 2019, with a value of $318 Million and a weighting of 44.11%. Carl L Gordon owns 2,027,550 shares of Turning Point Therapeutics Inc (TPTX) as of April 22, 2019, with a value of $154 Million and a weighting of 21.38%. Carl L Gordon also owns 17,713,600 shares of Theseus Pharmaceuticals Inc (THRX) as of July 17, 2023, with a value of $72 Million and a weighting of 9.98%. The other 15 stocks MBX Biosciences Inc (MBX) , ArriVent BioPharma Inc (AVBP) , Compass Therapeutics Inc (CMPX) , Intellia Therapeutics Inc (NTLA) , Alector Inc (ALEC) , BioCryst Pharmaceuticals Inc (BCRX) , ORIC Pharmaceuticals Inc (ORIC) , ACADIA Pharmaceuticals Inc (ACAD) , Adicet Bio Inc (ACET) , Terns Pharmaceuticals Inc (TERN) , Keros Therapeutics Inc (KROS) , Kinnate Biopharma Inc (KNTE) , Cartesian Therapeutics Inc (RNAC) , X4 Pharmaceuticals Inc (XFOR) , Pacira BioSciences Inc (PCRX) have a combined weighting of 24.53% among all his current holdings.

Latest Holdings of Carl L Gordon

Ticker Company Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
PRVL Prevail Therapeutics Inc 2019-06-24 13,822,463 23.00 317,916,649
TPTX Turning Point Therapeutics Inc 2019-04-22 2,027,550 76.01 154,114,076
THRX Theseus Pharmaceuticals Inc 2023-07-17 17,713,600 4.06 71,917,216
MBX MBX Biosciences Inc 2025-02-18 4,002,887 11.04 44,171,858
AVBP ArriVent BioPharma Inc 2024-01-30 1,513,664 20.08 30,394,373
CMPX Compass Therapeutics Inc 2025-04-09 15,219,994 1.75 26,709,567
NTLA Intellia Therapeutics Inc 2016-05-11 2,662,180 7.29 19,393,981
ALEC Alector Inc 2019-02-11 13,094,029 1.03 13,486,850
BCRX BioCryst Pharmaceuticals Inc 2005-12-02 1,100,000 9.99 10,989,000
ORIC ORIC Pharmaceuticals Inc 2021-03-30 2,212,571 4.77 10,542,901
ACAD ACADIA Pharmaceuticals Inc 2005-04-20 621,606 14.63 9,094,096
ACET Adicet Bio Inc 2024-01-25 11,447,140 0.54 6,181,456
TERN Terns Pharmaceuticals Inc 2024-07-16 755,635 3.09 2,331,134
KROS Keros Therapeutics Inc 2024-08-13 119,522 13.60 1,625,487
KNTE Kinnate Biopharma Inc 2023-05-05 450,000 2.65 1,192,500
RNAC Cartesian Therapeutics Inc 2016-06-27 60,847 10.41 633,113
XFOR X4 Pharmaceuticals Inc 2017-11-20 10,383 3.33 34,523
PCRX Pacira BioSciences Inc 2011-02-08 0 25.29 0

Holding Weightings of Carl L Gordon


Carl L Gordon Form 4 Trading Tracker

According to the SEC Form 4 filings, Carl L Gordon has made a total of 0 transactions in Prevail Therapeutics Inc (PRVL) over the past 5 years. The most-recent trade in Prevail Therapeutics Inc is the acquisition of 882,352 shares on June 24, 2019, which cost Carl L Gordon around $15 Million.

According to the SEC Form 4 filings, Carl L Gordon has made a total of 0 transactions in Turning Point Therapeutics Inc (TPTX) over the past 5 years. The most-recent trade in Turning Point Therapeutics Inc is the acquisition of 360,000 shares on April 22, 2019, which cost Carl L Gordon around $6 Million.

According to the SEC Form 4 filings, Carl L Gordon has made a total of 5 transactions in Theseus Pharmaceuticals Inc (THRX) over the past 5 years, including 5 buys and 0 sells. The most-recent trade in Theseus Pharmaceuticals Inc is the acquisition of 479,932 shares on July 17, 2023, which cost Carl L Gordon around $1 Million.

More details on Carl L Gordon's insider transactions can be found in the Insider Trading History of Carl L Gordon table.

Insider Trading History of Carl L Gordon

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Carl L Gordon Trading Performance

GuruFocus tracks the stock performance after each of Carl L Gordon's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Carl L Gordon is 6.69%. GuruFocus also compares Carl L Gordon's trading performance to market benchmark return within the same time period. The performance of stocks bought by Carl L Gordon within 3 months outperforms 15 times out of 30 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Carl L Gordon's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Carl L Gordon

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
15 out of 26 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 6.67 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 5.99 LIMIT LIMIT LIMIT LIMIT LIMIT

Carl L Gordon Ownership Network

Ownership Network List of Carl L Gordon

No Data

Ownership Network Relation of Carl L Gordon

Insider Network Chart


Carl L Gordon Owned Company Details

What does Prevail Therapeutics Inc do?

Who are the key executives at Prevail Therapeutics Inc?

Carl L Gordon is the director & 10 percent owner of Prevail Therapeutics Inc. Other key executives at Prevail Therapeutics Inc include director & 10 percent owner Peter A. Thompson , General Counsel Kira M. Schwartz , and Chief Development Officer Franz Hefti .

Prevail Therapeutics Inc (PRVL) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Prevail Therapeutics Inc (PRVL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Prevail Therapeutics Inc (PRVL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Prevail Therapeutics Inc (PRVL)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Prevail Therapeutics Inc Insider Transactions

No Available Data

Carl L Gordon Mailing Address

Above is the net worth, insider trading, and ownership report for Carl L Gordon. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Carl L Gordon's mailing address is: New York Ny 10022.